Antibody-drug conjugate
Antibody-drug conjugate (an•ti•bod•y-drug con•ju•gate, abbreviated as ADC) is a type of biopharmaceutical drug designed as a targeted therapy for treating patients with certain diseases.
Pronunciation
- Antibody: /ˈæntɪˌbɒdi/
- Drug: /drʌɡ/
- Conjugate: /ˈkɒndʒʊɡət/
Etymology
The term "antibody-drug conjugate" is derived from its components:
- "Antibody" comes from the Greek anti (against) and body (substance), referring to a protein produced by the body's immune system that recognizes and binds to foreign substances.
- "Drug" comes from the Old French drogue (supply, stock, provision), referring to a substance used for medical treatment.
- "Conjugate" comes from the Latin conjugare (to join together), referring to the process of linking two compounds.
Definition
An antibody-drug conjugate (ADC) is a medication that combines an antibody with a cytotoxic drug. Through the use of a linker, these two components are joined together, allowing the antibody to target specific cells (such as cancer cells), and then deliver the cytotoxic drug to these cells.
Related Terms
- Monoclonal antibody: A type of antibody made in the lab that can bind to substances in the body, including cancer cells.
- Cytotoxic drug: A medication that kills cells, especially cancer cells.
- Linker: A molecule that connects the antibody to the drug in an ADC.
- Targeted therapy: A type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells.
See Also
External links
- Medical encyclopedia article on Antibody-drug conjugate
- Wikipedia's article - Antibody-drug conjugate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski